Triple-negative breast cancer: Unique biology and its management

Rodrigo O.B. Maegawa, Shou Ching Tang

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu. It primarily, but not exclusively, carries the basal-like molecular profile on gene expression arrays and is associated with BRCA-1 and p53 mutations. It has an aggressive behavior and predilection for visceral metastasis, therefore accounting for its poor prognosis. Despite lacking targeted therapies, it is sensitive to anthracyclines and taxanes. Increasing knowledge has generated a better understanding of its pathophysiology, therefore leading to the development of directed therapies, although their validation still needs further investigation. This review focuses on its biology, management, evolving concepts, and future directions.

Original languageEnglish (US)
Pages (from-to)878-883
Number of pages6
JournalCancer Investigation
Volume28
Issue number8
DOIs
StatePublished - Sep 1 2010

Fingerprint

Triple Negative Breast Neoplasms
Taxoids
Anthracyclines
Progesterone Receptors
Transcriptome
Estrogen Receptors
Neoplasm Metastasis
Mutation
Therapeutics
Direction compound

Keywords

  • Breast cancers
  • Clinical trials
  • Tumor biology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Triple-negative breast cancer : Unique biology and its management. / Maegawa, Rodrigo O.B.; Tang, Shou Ching.

In: Cancer Investigation, Vol. 28, No. 8, 01.09.2010, p. 878-883.

Research output: Contribution to journalReview article

Maegawa, Rodrigo O.B. ; Tang, Shou Ching. / Triple-negative breast cancer : Unique biology and its management. In: Cancer Investigation. 2010 ; Vol. 28, No. 8. pp. 878-883.
@article{17cccf371f1f4aa7b7d9870e6eb24598,
title = "Triple-negative breast cancer: Unique biology and its management",
abstract = "Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu. It primarily, but not exclusively, carries the basal-like molecular profile on gene expression arrays and is associated with BRCA-1 and p53 mutations. It has an aggressive behavior and predilection for visceral metastasis, therefore accounting for its poor prognosis. Despite lacking targeted therapies, it is sensitive to anthracyclines and taxanes. Increasing knowledge has generated a better understanding of its pathophysiology, therefore leading to the development of directed therapies, although their validation still needs further investigation. This review focuses on its biology, management, evolving concepts, and future directions.",
keywords = "Breast cancers, Clinical trials, Tumor biology",
author = "Maegawa, {Rodrigo O.B.} and Tang, {Shou Ching}",
year = "2010",
month = "9",
day = "1",
doi = "10.3109/07357907.2010.483507",
language = "English (US)",
volume = "28",
pages = "878--883",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Unique biology and its management

AU - Maegawa, Rodrigo O.B.

AU - Tang, Shou Ching

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu. It primarily, but not exclusively, carries the basal-like molecular profile on gene expression arrays and is associated with BRCA-1 and p53 mutations. It has an aggressive behavior and predilection for visceral metastasis, therefore accounting for its poor prognosis. Despite lacking targeted therapies, it is sensitive to anthracyclines and taxanes. Increasing knowledge has generated a better understanding of its pathophysiology, therefore leading to the development of directed therapies, although their validation still needs further investigation. This review focuses on its biology, management, evolving concepts, and future directions.

AB - Triple-negative breast cancer is defined by the lack of expression of estrogen-receptor, progesterone-receptor, and HER-2/neu. It primarily, but not exclusively, carries the basal-like molecular profile on gene expression arrays and is associated with BRCA-1 and p53 mutations. It has an aggressive behavior and predilection for visceral metastasis, therefore accounting for its poor prognosis. Despite lacking targeted therapies, it is sensitive to anthracyclines and taxanes. Increasing knowledge has generated a better understanding of its pathophysiology, therefore leading to the development of directed therapies, although their validation still needs further investigation. This review focuses on its biology, management, evolving concepts, and future directions.

KW - Breast cancers

KW - Clinical trials

KW - Tumor biology

UR - http://www.scopus.com/inward/record.url?scp=77956632772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956632772&partnerID=8YFLogxK

U2 - 10.3109/07357907.2010.483507

DO - 10.3109/07357907.2010.483507

M3 - Review article

C2 - 20839950

AN - SCOPUS:77956632772

VL - 28

SP - 878

EP - 883

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 8

ER -